The fact that astragalin reduced the levels of p-NF-κB, p-IκBα, p65, TNF-α, and IL-6 suggests that astragalin may target NF-κB signaling as a strategy for colon cancer treatment (Yang et al., 2021). Here, NFKB1 is linked to colonic neoplasm.